Phase I Dose-escalation Study with Extended Daily Administration of Debio 1143, an Oral Inhibitor of Apoptosis Protein Inhibitor, in Patients with Solid Tumors

Presented at ASCO 2015, Chicago, USA

HC Pitot (1), HI Hurwitz (2), C Zanna (3), J Brill (4), G Vuagniaux (3), E Rouits (3), M Sorensen (4); DC Smith (5)

(1) Mayo Clinic,Rochester, USA;

(2) Duke University, Durham, USA;

(3) Debiopharm International SA, Switzerland;

(4) Ascenta Therapeutics, Malvern, USA;

(5) University ofMichigan, Ann Arbor, USA